TY - JOUR
T1 - Management of the insulin resistance syndrome.
AU - Desouza, C.
AU - Gilling, L.
AU - Fonseca, V.
N1 - Funding Information:
Diabetes research at the Tulane University Health Sciences Center is supported in part by the John C. Cudd Memorial fund and the Tullis-Tulane Alumni Chair in Diabetes.
PY - 2001/10
Y1 - 2001/10
N2 - The insulin resistance syndrome (IRS) is a common disorder, which has important clinical implications. It is a cluster of cardiovascular risk factors that include obesity, hypertension, dyslipidemia, glucose intolerance, and type 2 diabetes mellitus. Lifestyle modifications and insulin sensitizers are among the several therapeutic strategies available for the treatment of the IRS. Optimal treatment will not only improve glycemic control, but may also significantly lower cardiovascular disease.
AB - The insulin resistance syndrome (IRS) is a common disorder, which has important clinical implications. It is a cluster of cardiovascular risk factors that include obesity, hypertension, dyslipidemia, glucose intolerance, and type 2 diabetes mellitus. Lifestyle modifications and insulin sensitizers are among the several therapeutic strategies available for the treatment of the IRS. Optimal treatment will not only improve glycemic control, but may also significantly lower cardiovascular disease.
UR - http://www.scopus.com/inward/record.url?scp=0035497675&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035497675&partnerID=8YFLogxK
U2 - 10.1007/s11892-001-0026-6
DO - 10.1007/s11892-001-0026-6
M3 - Review article
C2 - 12643110
AN - SCOPUS:0035497675
VL - 1
SP - 140
EP - 147
JO - Current Diabetes Reports
JF - Current Diabetes Reports
SN - 1534-4827
IS - 2
ER -